Stereotactic Surgery Devices Market Size - By Product (Gamma Knife, LINAC, PBRT, CyberKnife), By Application (Liver, Breast, Prostate, Lung, Colon, Others) and By Region: Global & Forecast, 2024-2033

<p>Stereotactic Surgery Devices Market to reach USD 29.23 Bn in 2023, with steady growth projected to reach USD 44.1 Bn by 2033, at a 4.3% CAGR during 2024-2033.</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Description</td></tr><tr><th scope='row'>Market Size in 2023</th><td>USD 29.33 Billion</td></tr><tr><th scope='row'>Market Forecast in 2033</th><td>USD 44.1 Billion</td></tr><tr><th scope='row'>CAGR % 2024-2033</th><td>4.3%</td></tr><tr><th scope='row'>Base Year</th><td>2023</td></tr> <tr><th scope='row'>Historic Data</th><td>2016-2022</td></tr> <tr><th scope='row'>Forecast Period</th><td>2024-2033</td></tr> <tr><th scope='row'>Report USP</th><td>Production, Consumption, company share, company heatmap, company production capacity, growth factors and more</td></tr><tr><th scope='row'>Segments Covered</th><td>By Product, By Application and By Region</td></tr><tr><th scope='row'>Regional Scope</th><td>North America, Europe, APAC, South America and Middle East and Africa</td></tr><tr><th scope='row'>Growth Drivers</th><td>The demographic shift towards an aging population contributes to an increased incidence of age-related neurological disorders. Stereotactic surgery, with its ability to provide targeted treatments, becomes crucial in addressing the healthcare needs of an aging demographic. Growing awareness among healthcare professionals and patients about the benefits of stereotactic surgery contributes to its wider acceptance. Education initiatives and awareness campaigns highlight the effectiveness of these devices in treating various neurological conditions. The trend towards outpatient procedures and shorter hospital stays favors the adoption of stereotactic surgery devices. Patients often prefer procedures that allow for quicker recovery and reduced hospitalization, and stereotactic surgery aligns with these preferences.</td></tr> <tr><th scope='row'>Country Scope</th><td>U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria</td></tr><tr><th scope='row'>Key Companies</th><td>Varian Medical Systems, Inc., Elekta AB, Medtronic plc, Inomed Medizintechnik GmbH, Brainlab AG, Monteris Medical Inc., Micromar Indústria e Comércio Ltda., Accuray Incorporated, Isomedix, Inc., Möller Medical GmbH, Nexstim Plc, Alliance Oncology, Renishaw plc and Other.</td></tr></tbody></table>

<p>立体定向手术设备市场预计于2023年达到292.3亿美元，预计在2024至2033年间保持稳定的增长态势，届时市场规模将扩展至441亿美元，年复合增长率达到4.3%。</p><table><tbody><tr><th scope='row'>报告属性</th><td>描述</td></tr><tr><th scope='row'>2023年市场规模</th><td>293.3亿美元</td></tr><tr><th scope='row'>2033年市场预测</th><td>441亿美元</td></tr><tr><th scope='row'>2024-2033年CAGR%</th><td>4.3%</td></tr><tr><th scope='row'>基准年份</th><td>2023年</td></tr><tr><th scope='row'>历史数据</th><td>2016-2022年</td></tr><tr><th scope='row'>预测周期</th><td>2024-2033年</td></tr><tr><th scope='row'>报告独特卖点</th><td>生产、消费、公司市场份额、公司热点图、公司生产能力、增长因素等</td></tr><tr><th scope='row'>涵盖的细分市场</th><td>按产品、按应用和按地区</td></tr><tr><th scope='row'>区域范围</th><td>北美、欧洲、亚太地区、南美洲、中东及非洲</td></tr><tr><th scope='row'>增长动力</th><td>人口老龄化趋势导致与年龄相关的神经疾病发病率上升。立体定向手术凭借其精准治疗的能力，在满足老龄化群体的医疗需求方面变得至关重要。医疗专业人士和患者对立体定向手术益处的日益认识，促进了其更广泛的接受度。教育倡议和宣传活动突出了这些设备在治疗各种神经疾病方面的有效性。向门诊手术和缩短住院时间的趋势有利于立体定向手术设备的采用。患者通常更倾向于那些能够实现快速恢复和减少住院时间的手术，立体定向手术与此需求相契合。</td></tr><tr><th scope='row'>国家范围</th><td>美国；加拿大；英国；德国；法国；意大利；西班牙；比荷卢；北欧国家；俄罗斯；中国；印度；日本；韩国；澳大利亚；印度尼西亚；泰国；墨西哥；巴西；阿根廷；沙特阿拉伯；阿联酋；埃及；南非；尼日利亚</td></tr><tr><th scope='row'>主要公司</th><td>瓦里安医疗系统公司（Varian Medical Systems, Inc.）、伊莱克特拉公司（Elekta AB）、美敦力公司（Medtronic plc）、伊诺美德医疗技术公司（Inomed Medizintechnik GmbH）、脑图公司（Brainlab AG）、蒙特里斯医疗公司（Monteris Medical Inc.）、米克马尔工业和商业公司（Micromar Indústria e Comércio Ltda.）、准确射线公司（Accuray Incorporated）、艾索美迪克斯公司（Isomedix, Inc.）、莫勒医疗公司（Möller Medical GmbH）、内斯特姆公司（Nexstim Plc）、联盟肿瘤学公司（Alliance Oncology）、雷尼沙公司（Renishaw plc）及其他公司。</td></tr></tbody></table>